Chong Kun Dang Pharmaceutical Corp.
185750KOSPIPharmaceuticals
Chong Kun Dang Pharmaceutical Corp. (185750, KOSPI) reported KRW 1,692bn revenue in 2025.
Broker research: target prices and ratings
1 report from 1 firm between 2026-08-24 and 2026-08-24. One firm stated a target price: KRW 110,000.
Newest first. Ratings are as each firm stated them, translated into English. "Not stated" means the report carried no value — it is not a zero.
| Date | Target price | Rating | Firm | Analyst |
|---|---|---|---|---|
| KRW 110,000 | Buy | Mirae Asset Securities | Not stated |
Report titles are not shown: the source lists them in Korean only, and we do not publish our own translation of another firm's headline.
This is a record of what brokers published, not investment advice. It is a sample of broker research — the reports our collection picked up, not every report written on this company — and the range and median describe that sample, not a market consensus. These are statistics, not a verdict.
Source: broker reports collected by SeoulMarkets from Naver Finance's research listing and from brokers' own websites, 2026-06-29 to 2026-10-28.
Compare target prices across Korean biotech and pharma stocks →
Reported financials
Figures are as filed with the Korean regulator, in billions of won (KRW bn). We do not convert to dollars — an exchange rate would be a number we made up, not one the company reported.
| Year | Revenue | Operating profit | Net profit | Assets | Equity | Basis |
|---|---|---|---|---|---|---|
| 2021 | 1,344 | 95 | 42 | 1,047 | 566 | Consolidated |
| 2022 | 1,488 | 110 | 80 | 1,125 | 621 | Consolidated |
| 2023 | 1,669 | 247 | 214 | 1,402 | 816 | Consolidated |
| 2024 | 1,586 | 99 | 111 | 1,459 | 896 | Consolidated |
| 2025 | 1,692 | 81 | 78 | 1,800 | 1,006 | Consolidated |
Ratios, year by year
Each ratio is computed inside its own year. A dash means the input was missing or the denominator was zero — not that the value is zero.
| Year | Operating margin | Net margin | Equity / assets | Return on equity |
|---|---|---|---|---|
| 2021 | 7.1% | 3.2% | 54.1% | 7.5% |
| 2022 | 7.4% | 5.4% | 55.2% | 12.9% |
| 2023 | 14.8% | 12.8% | 58.2% | 26.2% |
| 2024 | 6.3% | 7% | 61.4% | 12.4% |
| 2025 | 4.8% | 4.6% | 55.9% | 7.7% |
Revenue moved 26% between 2021 and 2025.
Net profit was positive in the 5 most recent consecutive years on file — every year we hold. Counted from the 5 years in which the company filed a net-profit line — a year with no filing is skipped, not read as a loss.
These are arithmetic, not judgements. We do not say whether a margin is good or bad, and we do not rank companies against each other.
Market size
| Market capitalisation | KRW 932bn |
|---|---|
| Close price | KRW 67,500 |
| Listed shares | 13,802,780 |
| Price as of | 20260909 |
Market capitalisation is what buyers are betting the company is worth. It is not something the company produced, so we never present it as output or productivity.
When it was founded
The incorporation date on the company's registration record, as filed with Korea's Financial Supervisory Service. This is when the company was legally formed — not when it first listed, and not when the business it grew out of began trading.
| Incorporated |
|---|
Workforce — a side measure, not the main one
| Employees (2025) | 2,304 |
|---|---|
| Women | 735 (31.9%) |
| Average tenure | 10 years |
| Annual pay, men | KRW 85,000,000 |
| Annual pay, women | KRW 68,000,000 |
| Pay ratio, women to men | 80% |
Other companies in Pharmaceuticals
181 listed companies file under this classification. Showing 12.